Central government’s recent approval for Covaxin manufactured by Bharat Biotech Ltd under emergency use against Covid-19 has sparked an investor frenzy.
Government of India has placed an order for 5.5 million doses of Covaxin at an average price of Rs 206 from Bharat Biotech. According to a statement issued by the Chairman & Managing Director of Bharat Biotech International Limited, Dr Krishna Ella the company has already produced 20 million doses and intends to make 150 million doses before July or August. Bharat Biotech’s Covaxin is India’s first indigenous coronavirus vaccine.
Earlier in the end of November amid speculations that Pfizer was in talks with the Indian government for vaccine deal, Pfizer\’s share price gained by 8% over the next few days.
Anticipating another brilliant investment opportunity in Bharat Biotech, search engines on the internet are flooded with queries from investors like:
How can I invest in Bharat Biotech shares?
How to buy shares of Bharat Biotech?
What is the share price of Bharat Biotech?
Is Bharat Biotech listed on the stock exchange?
As Bharat Biotech is a privately held company, its shares are not listed on India\’s stock exchanges. Some investors have mistakenly invested in another company with a similar name, Bharat Immunologicals and Biologicals Corporation Ltd. which is listed on the stock exchanges.
Bharat Immunologicals and Biologicals Corporation Ltd. is a public sector unit established under the Department of Biotechnology, Ministry of Science & Technology by the central government. The company is the pioneer in the field of polio vaccines, with over 60% of total market share in India and also produces a wide range of pharma products including vaccines for oral polio, medicines for diarrhea and zinc tablets.
Investors should not confuse Bharat Biotech with Bharat Immunologicals and Biologicals Corporation Ltd.
Established in 1996, Bharat Biotech has pioneered the development of the indigenous Rotavirus vaccine and Hepatitis B vaccine at affordable price. The company makes and supplies several vaccines, including polio, rabies, and typhoid for domestic use and exports.
Bharat Biotech has many firsts to its credit, including the manufacture of a preservative-free vaccine for Hepatitis B, India’s first cell-cultured swine-flu vaccine, manufacture the world’s cheapest Hepatitis vaccine and the development of a vaccine for the Zika virus. The company till date has supplied over 3 billion doses of vaccines globally.
Bharat Biotech’s state-of-the-art manufacturing facility in Genome Valley, Hyderabad, India is the largest facility of its kind in the Asia-Pacific region. According to the Bloomberg Quint, Bharat Biotech was 73% owned by the Ella family as of March 2020. Besides Dr Krishna Ella, his wife Suchitra Ella and Biotech Consortia Inc. are large owners from the promoter group.
Bharat Biotech is an unlisted company, and hence currently it is not possible for investors to invest in Bharat Biotech shares on the stock exchanges. For investors on the lookout for exciting wealth creation investment opportunities, there are many such stocks available. Stocks of companies with the potential to grow investor wealth by 4-5 times over the next 5-6 years as India transitions from a developing economy to a developed economy.
Click here to invest in 20-25 multibagger stocks chosen after detailed research by our team of research experts.